title: In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
authors.forename: Alan
authors.initials: A
authors.lastname: Hatfield
authors.forename: Samantha
authors.initials: S
authors.lastname: Owen
authors.forename: Paul Richard
authors.initials: PR
authors.lastname: Pilot
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001549:Benzamides; D006333:Heart Failure / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate